Beginning with oncology, C4T is advancing multiple internal and partnered investigational degraders towards the clinic. Our balanced approach to target different cancers maximizes patient impact.
We are advancing two types of protein degraders, each of which is intended to result in the same end point — the specific degradation of the target proteins of interest:
We refer to the first type of degrader as MonoDACs™, which are Monofunctional Degradation Activating Compounds, which function by binding to E3 ligases and creating a new surface on the E3 ligases that enhances the binding of the E3 ligases to target proteins. MonoDACs are sometimes referred to as “glue degraders.”
We refer to our second type of degrader as BiDACs™, which are Bifunctional Degradation Activating Compounds, which are designed so that one end of the molecule binds to the disease-causing target protein and the other end binds to the E3 ligase. BiDACs are sometimes referred to as “heterobifunctional degraders.“